Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONGeneric

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Standard Dose
0.25MG/INH;EQ 0.05MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE is listed in Drugs@FDA under application 214464 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE Form and strength POWDER;INHALATION - 0.25MG/INH;EQ 0.05MG BASE/INH Sponsor RESPIRENT PHARMS Submission history Latest submission status date: 2026-01-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE is listed in Drugs@FDA under application 214464 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE Form and strength POWDER;INHALATION - 0.25MG/INH;EQ 0.05MG BASE/INH Sponsor RESPIRENT PHARMS Submission history Latest submission status date: 2026-01-12 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE (FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE) | Drug Monograph | MedicHelpline